OBJECTIVE: To probe into the effect of dabigatran combined with aspirin after percutaneous coronary intervention （PCI）. METHODS: Totally 159 patients with coronary disease undergoing PCI admitted into the First Hospital of Xi’an from Jun. 2016 to Jun. 2019 were selected and divided into research group （80 cases） and control group （79 cases） via random number table. Both groups were given aspirin orally after surgery

on that basis

the research group was treated with dabigatran

both groups were treated continuously for 3 months. Differences in changes of coagulation function indicators [prothrombin time （PT）

thrombin time （TT）

international normalized ratio （INR） and activated partial thromboplastin time （APTT） ] and hemorheological indicators

incidences of bleeding events and adverse cardiovascular and cerebrovascular events between two groups were compared. RESULTS: Before treatment

there were no statistical significance in differences in indicators of coagulation function and hemorheology between two groups （P>0. 05）. After treatment

the PT

TT and APTT of both groups had been significantly prolonged

the INR level had been significantly increased

the plasma viscosity ratio

hematokrit and whole blood viscosity ratio had been significantly decreased

and the improvements of all those indicators in research group were significantly better than the control group

with statistically significant differences （P < 0. 05）. The total incidence of adverse cardiovascular and cerebrovascular events such as myocardial infarction

sudden cardiac death

cerebral infarction

angina recurrence and stent thrombosis of research group was significantly lower than those of control group

with statistically significant difference （P < 0. 05）. The total incidences of bleeding events of research group and control group were respectively 2. 50% （2/80） and 8. 86% （7/79）

the difference had no statistical significance （P > 0. 05）. CONCLUSIONS: The application of dabigatran combined with aspirin for anticoagulation therapy in patients with coronary heart disease after PCI can effectively improve the coagulation function

reduce the incidence of adverse cardiovascular and cerebrovascular events after surgery.